146 related articles for article (PubMed ID: 10503729)
41. Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
Yokosuka O
J Gastroenterol; 2004 Aug; 39(8):813-4. PubMed ID: 15338383
[No Abstract] [Full Text] [Related]
42. Hepatitis B virus infection--natural history and clinical consequences.
Ganem D; Prince AM
N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
[No Abstract] [Full Text] [Related]
43. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Bourlière M
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
[No Abstract] [Full Text] [Related]
44. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
45. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
[TBL] [Abstract][Full Text] [Related]
46. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
47. [Lamivudine therapy for chronic hepatitis B].
Daikoku M; Koga M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():321-5. PubMed ID: 15453338
[No Abstract] [Full Text] [Related]
48. Natural infection of HBV DNA YMDD variant strains in a chronic hepatitis B patient before treatment with lamivudine.
Yang DH; Liang WF; Zhao NF; Xie YJ
Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):539-40. PubMed ID: 14607683
[No Abstract] [Full Text] [Related]
49. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Chen JY; Wang LW; Sun XM; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
[TBL] [Abstract][Full Text] [Related]
50. Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation?
Farrell GC
J Gastroenterol Hepatol; 1999 Aug; 14(8):741-4. PubMed ID: 10482423
[No Abstract] [Full Text] [Related]
51. [Chronic hepatitis B: natural history and treatments].
Bailly F; Zoulim F
Gastroenterol Clin Biol; 2002 May; 26(5):492-500. PubMed ID: 12122361
[No Abstract] [Full Text] [Related]
52. [Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
Zarski JP
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S20-1. PubMed ID: 17075491
[No Abstract] [Full Text] [Related]
53. [Long-term history of chronic hepatitis B virus infection in children].
Fujisawa T; Inui A; Sogo T; Komatsu H
Nihon Rinsho; 2004 Aug; 62 Suppl 8():303-8. PubMed ID: 15453335
[No Abstract] [Full Text] [Related]
54. [Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Marcellin P; Lada O
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S5-8. PubMed ID: 17075487
[No Abstract] [Full Text] [Related]
55. [Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Benhamou Y
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S22-5. PubMed ID: 17075492
[No Abstract] [Full Text] [Related]
56. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
57. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
[TBL] [Abstract][Full Text] [Related]
58. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
[TBL] [Abstract][Full Text] [Related]
59. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
60. [YMDD motif and its significance].
Goto T; Kato N; Omata M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():46-50. PubMed ID: 15453283
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
